Research letterTreatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
References (5)
- et al.
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
J Am Acad Dermatol
(2016) - et al.
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
J Am Acad Dermatol
(2017)
Cited by (53)
Vitiligo: An immune disease and its emerging mesenchymal stem cell therapy paradigm
2023, Transplant ImmunologyCitation Excerpt :These effects lead to the recruitment of CD8+ CTLs in skin lesions for secondary damage to melanocytes [81]. Numerous studies reported that JAK inhibitors can inhibit the IFN-γ-dependent JAK/STAT pathway to reduce IFN-γ and the secretion of CXCL9 and CXCL10, thereby reducing the damage caused by CD8+ CTLs to melanocytes [82–86]. In addition, in skin lesions of patients with vitiligo, JAK1 and JAK3 were highly expressed.
Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients With Vitiligo
2022, Journal of Investigative DermatologyVitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling
2022, Journal of Investigative DermatologyCitation Excerpt :Emerging treatments mainly rely on targeting the immune system (Migayron et al., 2020). In this context, Jak inhibitors have shown promising results in clinical trials (Craiglow and King, 2015; Harris et al., 2016; Joshipura et al., 2018; Liu et al., 2017; Olsen et al., 2020; Rothstein et al., 2017). Their efficacy is attributed to the targeting of immune cells, including T cells, and to the inhibition of IFN-γ signaling (Frisoli et al., 2020).
Janus kinase inhibitors in dermatology: Part II. A comprehensive review
2022, Journal of the American Academy of DermatologyCitation Excerpt :Moreover, when treating vitiligo with JAK inhibitors, concomitant light exposure may enhance the treatment response, as JAK inhibitors are thought to suppress T-cell-mediated melanocyte destruction, while light therapy stimulates melanocyte regeneration.18 A number of studies have shown promise for the use of JAK inhibitors in the treatment of vitiligo (Table III).19-24 Environmental exposure, genetic predisposition, and immunologic mechanisms underly the pathogenesis of sarcoidosis.
Advances in vitiligo therapy
2021, Piel
Funding sources: None.
Conflicts of interest: Dr Rosmarin has served on advisory boards or is a consultant to Pfizer, Eli Lilly, Abbvie, Janssen, Regeneron, Sanofi, Celgene, and Novartis. Dr Rosmarin also serves as an investigator for Incyte. Other authors do not have disclosures to report.